Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Beckman Coulter
| Company | Beckman Coulter |
|---|---|
| Name of instrument | DxC 500i Clinical Analyzer |
| Contact | Shannon Garegnani |
| City, State | Brea, CA |
| Phone | 800-526-3821 |
| Website | |
| Type of instrument | combination chemistry/immunoassay |
| Operational type/Model type | continuous random access/floor standing |
| List price/First year sold in U.S. | —/2025 |
| Targeted hospital bed size/Targeted test volume | —/annual: 50,000–350,000 |
| Company manufactures instrument | yes (also sold by distribution partners) |
| Other models in this family of analyzers | DxC 500 AU, DxC 700 AU, AU5800, Access 2, DxI 600, DxI 9000 |
| No. of units in clinical use in U.S./Outside U.S. (countries) | —/— (worldwide) |
| Dimensions (H × W × D)/Instrument footprint | 48.8 × 100 × 30.3 in./21 sq. ft. |
| Weight empty/Weight fully loaded | 1,430 lbs./— |
| No. of different measured assays onboard simultaneously | — |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | 800 chemistry with ISE, 100 immunoassay/— |
| No. of direct ion-selective electrode channels | — |
| Detection methods | photometry, potentiometry |
| Stat time until completion/specimen throughput for ion-selective electrode | — |
| Stat time until completion/specimen throughput for basic metabolic panel | — |
| Stat time until completion/specimen throughput for complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | chemiluminescence |
| Separation methodologies | — |
| Stat time until completion of a ß-hCG test | — |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Approximate No. of tests per reagent set/Reagent type | 50–6,744 per pack (varies by assay)/— |
| Reagents refrigerated onboard/Reagents ready to use | yes (4.5°–12°C)/variable; reagent specific |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (open reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/168 specimens |
| Design of sample-handling system | rack |
| Uses washable cuvettes/Uses disposable cuvettes | yes (can store up to 88 cuvettes)/no |
| Min.–max. sample volume that can be aspirated at one time | 1–25 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 90 µL/50 µL/80 µL |
| Dedicated pediatric sample cup | no |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/— |
| Pierces caps on primary tubes | no |
| Protects against probe collision | yes |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | detection for hemolysis, icterus, lipemia, clots |
| Dilutes patient samples onboard/Susceptibility to carryover | yes (can be programmed to perform dilutions prior to analysis)/— |
| Automatic rerun capability | yes |
| Sample volume can be diluted to rerun out-of-linear-range high results | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Autocalibration/Multipoint calibration supported | yes (calibrants are not stored onboard)/yes |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | 1 day/—/—/1–90 days/— |
| Automatic programmable start/Automatic programmable shutdown | — |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | direct to drain |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, Code 39, Code 128, NW7, EAN-13, ISBT 128, Standard 2 of 5)/— |
| Lab can control analyzer from remote computer | yes |
| Instrument can diagnose its own malfunctions | yes (instrument can order malfunctioning parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/Medicus, Evident, CGM LabDaq, Oracle Health, Clinisys |
| LIS interface provided/Bidirectional interface capability | yes (additional cost)/yes (host query) |
| Modem servicing provided/Service engineer on-site response time | — |
| Mean time between failures | — |
| Average scheduled maintenance time by lab personnel | daily: 9 min.; weekly: 26 min.; monthly: 45 min. |
| Maintenance records kept onboard for user/vendor | yes/no |
| Maintenance training demonstration module onboard | yes |
| Training included with purchase/Avg. time for basic user training | yes (2 training slots)/— (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at vendor site)/— |
| Warranty provided/Cost of annual service contract (24 h/7 d) | — |
| Distinguishing features (supplied by company) | independent and integrated operations, reagent load on the fly, rapid throughput; single point of sample loading, intuitive interface and guided workflows, easy to maintain parts; offers a menu of more than 170 assays for complete disease state management |